Kathleen O’Brien looks at how to bring worldwide adverse event (AE) reporting under control – and why it matters
Pharmacovigilance has never been a bigger undertaking than it is today. During the COVID-19 pandemic, workloads have soared and despite self-isolation and social distancing, those already vulnerable have become more so. Patients who are taking drugs long-term due to pre-existing conditions tend to be at higher risk for COVID-19 meaning that some risk factors have multiplied and clinicians have had to be extra vigilant.
So what’s the best approach to centralising and streamlining AE reporting, with a view to staying ahead of regulatory deadlines and maximising the strategic insights from incoming safety signals?
In this article, Kathleen O'Brien explores some practical steps that companies can take.Click here to read the full content of this article in the digital magazine